Drugs / IBI315
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04162327 | Nov 2019 → Jan 2022 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05608785 | Jan → Dec 2023 | gastric cancer, gastroesophageal cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162327 ↗ |
| Route | Intravenous | “intravenous drip” NCT05608785 ↗ |